SUBSCRIBE TO GET OUR FREE ALERTS TODAY
- Don't Trade AVXL until you read a Full Report!
- Get Alert's on companies like AVXL BEFORE the Rest.
- Is AVXL a Buy? Receive Exclusive Research and Analysis.
- Find out what AVXL Insiders don't want you to know.
AVXL Stock News
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference 03/25/2024 11:30 AMNEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will present at the 23rd Annual Needham Virtual Healthcare Conference, April
- Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia 03/18/2024 11:30 AMFirst patient screened ahead of schedule Trial to investigate positive, negative, and cognitive domains of schizophrenia ANAVEX®3-71’s differentiated dual novel mechanism of action offers the potential to synergistically activate both SIGMAR1 and M1 muscarinic receptors and treat all symptom domains of schizophrenia without the side effects of standard of care antipsychotics NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clin
- 12 $10 Stocks That Will Triple 02/26/2024 06:14 PMIn this article, we discuss 12 $10 stocks that will triple. If you want to skip our discussion on the latest stock market landscape, head over to 5 $10 Stocks That Will Triple. According to JPMorgan, the global outlook for securities markets in 2024 suggests a more positive scenario compared to the previous year, with […]
- Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference 02/26/2024 12:30 PMNEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will present at the 44th Annual TD Cowen Health Care Conference, March 4-6, 2
- Anavex Life Sciences Corp. (NASDAQ:AVXL) Q1 2024 Earnings Call Transcript 02/08/2024 02:39 PMAnavex Life Sciences Corp. (NASDAQ:AVXL) Q1 2024 Earnings Call Transcript February 7, 2024 Anavex Life Sciences Corp. beats earnings expectations. Reported EPS is $-0.0001, expectations were $-0.14. AVXL isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. Welcome to […]
Join the Stock Event that’s Sweeping Wall Street!
We’re Not your “Everyday” Stock Newsletter
In a world where Newsletters churn out pick after pick everyday, with little or no research that are usually more “miss” than hit, StockoftheWeek.com has come to break the cycle and end the madness!
ONE BIG PICK. ONCE A WEEK
We don’t overburden our members with junk. We take our time to research, analyze, and do our due diligence. Every profile, both compensated & uncompensated, must meet our strict criteria. Our goal is to provide members with One Big Profile per week. Each week’s new profile is a highly anticipated, CAN’T-MISS EVENT. And for good reason…
IMPECCABLE TRACK RECORD
“It takes 20 years to build a reputation and five minutes to ruin it. If you think about that you’ll do things differently.” Legendary Investor, Warren Buffett
Our track record is our reputation. And you can be sure we don’t take it lightly. That’s why we strive to be the Top Financial Newsletter on the Street Today. Subscribe today!